Showing 7321-7330 of 8649 results for "".
- Bausch Health Continuing Process Toward Separating Bausch + Lombhttps://modernod.com/news/bausch-health-continuing-process-toward-separating-bausch-lomb/2481048/Bausch Health Companies announced it is moving toward separating Bausch + Lomb after transferring common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing wholly-owned unrestricted subsidiary of the company.
- Glaukos Licenses Iveena’s Investigational Keratoconus Therapyhttps://modernod.com/news/glaukos-licenses-iveenas-investigational-keratoconus-therapy/2481044/Glaukos has acquired an exclusive global license to develop and commercialize iVeena Delivery Systems' investigational pharmacologic treatment for keratoconus, IVMED-80. As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with development
- Study: Bioengineered Cornea Can Restore Sight to the Blind and Visually Impairedhttps://modernod.com/news/study-bioengineered-cornea-can-restore-sight-to-the-blind-and-visually-impaired/2481039/Researchers and entrepreneurs have developed an implant made of collagen protein from pig’s skin, which resembles the human cornea. In a pilot study, the implant restored vision to 20 people with diseased corneas, most of whom were blind prior to receiving the implant, according to Link&oum
- SAV-IOL to Showcase IOL Technology at ESCRS 2022https://modernod.com/news/sav-iol-to-showcase-new-iol-technology-at-escrs-2022/2481038/After nearly 3 years of virtual congresses and canceled tradeshows worldwide, SAV-IOL announced it will be exhibiting at this year’s ESCRS event in Milan, Italy, September 16-19 at stand B14 at MiCo Convention Centre. SAV-IOL invites all participants to come check out their E
- BVI Installs First Beyeonics One Systemhttps://modernod.com/news/bvi-installs-first-beyeonics-one-system/2481035/BVI announced that the first Beyeonics One System has been installed at Holzman Solomon Vision Partners, in McClean, Virginia. On August 17, Jonathon Solomon, MD, was the first US surgeon to offer ophthalmic surgery with the Beyeonics One platform in private practice. Under th
- Visibly Becomes First FDA-Cleared Online Vision Test in the United Stateshttps://modernod.com/news/visibly-becomes-first-fda-cleared-online-vision-test-in-the-united-states/2481033/Visibly, the developer of an at-home digital vision testing platform, announced that it has received 510(k) clearance from the FDA for its Visibly Digital Acuity Product (VDAP). Visibly said it is the first FDA-cleared online visual acuity test on the US market. View Eyew
- First SBL-3 ClearView Multifocal Intraocular Lens Implanted in UShttps://modernod.com/news/first-sbl-3-clearview-multifocal-intraocular-lens-implanted-in-us/2481031/Lenstec announce that the first US commercial implantations of their newly FDA approved SBL-3 ClearView Multifocal IOL (MIOL) were performed by Jeff Whitsett, MD, of Whitsett Vision, Houston, Texas. The SBL-3 Clearview Multifocal is a next-generation presbyopia-
- Staar Surgical Partners with Joe Jonas to Introduce New EVO ICLhttps://modernod.com/news/staar-surgical-partners-with-joe-jonas-to-introduce-new-evo-icl/2481024/Staar Surgical announced its partnership with singer, songwriter, and actor, Joe Jonas, to raise awareness of its EVO Visian Implantable Collamer Lenses (EVO). EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia and astigmatism. Mr. Jo
- Study: Neurolenses Have Significant Impact on Reading Speedhttps://modernod.com/news/neurolenses-have-significant-impact-on-reading-speed/2481017/As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader population focused on visual performance and producti
- Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Diseasehttps://modernod.com/news/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-for-the-treatment-of-meibomian-gland-disease/2481015/Tarsus Pharmaceuticals announced that it has enrolled the first patient in a phase 2a clinical trial studying TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of meibomian gland disease (MGD) in patients with Demodex mites. Demodex